Matches in SemOpenAlex for { <https://semopenalex.org/work/W2772897485> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2772897485 endingPage "859" @default.
- W2772897485 startingPage "859" @default.
- W2772897485 abstract "Purpose. Abnormal glucose homeostasis may occur after pancreas transplantation after months of years from transplantation. Causes of beta-cell dysfunction are numerous including rejection, autoimmunity recurrence or drug toxicity. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide was evaluated to treat glucose disorders after pancreas transplantation. Methods. Six patients (4 men and 2 women) were included in a pilot, observational and single centre study. Five patients were recipients of a simultaneous pancreas-kidney transplantation and 1 of an isolated pancreas. At inclusion, all patients had an abnormal haemoglobin A1C (HbA1C) level (>6.0%). One patient was receiving repaglinide and 1 acarbose. All patients were under standard doses of tacrolimus and mycophenolate mofetil for maintenance immunosuppression. Liraglutide was initiated subcutaneously at 0.6 mg/day for 7 days and 1.2 mg/day thereafter. Clinical and metabolic follow-up was evaluated during a 6-month period. Results. At inclusion, mean time from transplantation was 69 months. Mean HbA1C level was 7.0% (range, 6.2 to 8.4%). Liraglutide was well tolerated without any interruption in 5 patients. One patient required discontinuation at 1 month, due to gastro-intestinal (GI) disorders. At 6 months, HbA1C level decreased in all patients receiving liraglutide, with a mean decreased value of 0.9% (up to -2.7%). Insulin secretion significantly improved in all patients when tested by an oral glucose tolerance test. Body weight decreased of 1.6 kg (from -6.4 to +3.0). GI disorders were noted in 3 patients including the previous described patient requiring definitive drug interruption. No interference with immunosuppressive agents was noted during the 6 months evaluation; doses of immunosuppressants remained unchanged. No increase in serum lipase was noted. Conclusion. In pancreas transplant recipients with abnormal glucose homeostasis, liraglutide seemed efficacious and well tolerated. This strategy could represent an alternative therapy to exogenous insulin." @default.
- W2772897485 created "2017-12-22" @default.
- W2772897485 creator A5003749091 @default.
- W2772897485 creator A5004521406 @default.
- W2772897485 creator A5012841449 @default.
- W2772897485 creator A5040930081 @default.
- W2772897485 creator A5043484813 @default.
- W2772897485 creator A5085398753 @default.
- W2772897485 date "2014-07-01" @default.
- W2772897485 modified "2023-10-14" @default.
- W2772897485 title "GLP-1 Agoniste Liraglutide for Endocrine Pancreas Dysfunction After Pancreas Transplantation." @default.
- W2772897485 doi "https://doi.org/10.1097/00007890-201407151-02934" @default.
- W2772897485 hasPublicationYear "2014" @default.
- W2772897485 type Work @default.
- W2772897485 sameAs 2772897485 @default.
- W2772897485 citedByCount "0" @default.
- W2772897485 crossrefType "journal-article" @default.
- W2772897485 hasAuthorship W2772897485A5003749091 @default.
- W2772897485 hasAuthorship W2772897485A5004521406 @default.
- W2772897485 hasAuthorship W2772897485A5012841449 @default.
- W2772897485 hasAuthorship W2772897485A5040930081 @default.
- W2772897485 hasAuthorship W2772897485A5043484813 @default.
- W2772897485 hasAuthorship W2772897485A5085398753 @default.
- W2772897485 hasConcept C126322002 @default.
- W2772897485 hasConcept C126894567 @default.
- W2772897485 hasConcept C134018914 @default.
- W2772897485 hasConcept C2777180221 @default.
- W2772897485 hasConcept C2778064082 @default.
- W2772897485 hasConcept C2778715236 @default.
- W2772897485 hasConcept C2780252810 @default.
- W2772897485 hasConcept C2780303639 @default.
- W2772897485 hasConcept C2781308992 @default.
- W2772897485 hasConcept C2909675724 @default.
- W2772897485 hasConcept C2911091166 @default.
- W2772897485 hasConcept C555293320 @default.
- W2772897485 hasConcept C71924100 @default.
- W2772897485 hasConcept C90924648 @default.
- W2772897485 hasConceptScore W2772897485C126322002 @default.
- W2772897485 hasConceptScore W2772897485C126894567 @default.
- W2772897485 hasConceptScore W2772897485C134018914 @default.
- W2772897485 hasConceptScore W2772897485C2777180221 @default.
- W2772897485 hasConceptScore W2772897485C2778064082 @default.
- W2772897485 hasConceptScore W2772897485C2778715236 @default.
- W2772897485 hasConceptScore W2772897485C2780252810 @default.
- W2772897485 hasConceptScore W2772897485C2780303639 @default.
- W2772897485 hasConceptScore W2772897485C2781308992 @default.
- W2772897485 hasConceptScore W2772897485C2909675724 @default.
- W2772897485 hasConceptScore W2772897485C2911091166 @default.
- W2772897485 hasConceptScore W2772897485C555293320 @default.
- W2772897485 hasConceptScore W2772897485C71924100 @default.
- W2772897485 hasConceptScore W2772897485C90924648 @default.
- W2772897485 hasLocation W27728974851 @default.
- W2772897485 hasOpenAccess W2772897485 @default.
- W2772897485 hasPrimaryLocation W27728974851 @default.
- W2772897485 hasRelatedWork W1893922067 @default.
- W2772897485 hasRelatedWork W1978004149 @default.
- W2772897485 hasRelatedWork W1999523305 @default.
- W2772897485 hasRelatedWork W2073397571 @default.
- W2772897485 hasRelatedWork W2076749355 @default.
- W2772897485 hasRelatedWork W2077310477 @default.
- W2772897485 hasRelatedWork W2126117849 @default.
- W2772897485 hasRelatedWork W3147651394 @default.
- W2772897485 hasRelatedWork W384548141 @default.
- W2772897485 hasRelatedWork W4237896243 @default.
- W2772897485 hasVolume "98" @default.
- W2772897485 isParatext "false" @default.
- W2772897485 isRetracted "false" @default.
- W2772897485 magId "2772897485" @default.
- W2772897485 workType "article" @default.